Work

The Rosiglitazone Story — Lessons from an FDA Advisory Committee Meeting

Year: 2007
Type: article
Abstract: On July 30, the Endocrinologic and Metabolic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee of the FDA concluded that the use of rosiglitazone for the treatment of type 2 diabetes was associated with an increased risk of myocardial ischemic events. Dr. Clifford Rosen reports.
Institution: St. Joseph Hospital
Language: English
Field: Medicine
Open Access status: bronze
OpenAlex ID: W2024874163
FWCI: 23.32
Cites: 4
Cited by: 210
Related to: 9